FDA Grants Priority Review for Nuvalent's Neladalkib, Sets November 27 PDUFA Date
NUVL sits 49% above its 52-week low of $70.25.
Summary
The FDA has accepted Nuvalent's New Drug Application for neladalkib with Priority Review, setting a PDUFA target action date of November 27, 2026. This follows the NDA submission announced in April and significantly accelerates the potential market entry for this key ALK-positive NSCLC candidate. The company also appointed Georg Pirmin Meyer as Chief International Officer, signaling a strategic push for global commercialization. This dual announcement strengthens Nuvalent's path towards bringing its pipeline to patients worldwide. Investors will watch for the upcoming ASCO presentation for further data and the November PDUFA date.
At the time of this announcement, NUVL was trading at $104.95 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $8.3B. The 52-week trading range was $70.25 to $113.02. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: PR Newswire.